Analytical Data
-
Gene name
DHRS7
- Application
-
Alternative Names
Retinal short-chain dehydrogenase/reductase 4 ;retSDR4Short chain dehydrogenase/reductase family 34C member 1
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y394
-
Expression Region
29-339aa
-
Molecular Weight
50.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DHRS7, or Dehydrogenase/Reductase 7, is a member of the short-chain dehydrogenase/reductase (SDR) superfamily, which plays crucial roles in various metabolic processes through its enzymatic activities, including the reduction of ketones and aldehydes. Research has shown that DHRS7 is implicated in the metabolism of retinoids, which are essential for vision and cellular differentiation. Aberrant expression of DHRS7 has been linked to several diseases, including certain cancers and metabolic disorders, highlighting its potential as a therapeutic target. Furthermore, the understanding of its structure and function can lead to advancements in drug development, as elucidating the mechanisms of action may provide insights into modulating its activity for clinical benefits. A comprehensive examination of DHRS7's biochemical properties and its interactions within metabolic pathways is therefore essential, fostering the growing interest in this protein within biomedical research. Through recombinant protein technology, DHRS7 can be produced in sufficient quantities for detailed studies, enabling the exploration of its kinetic properties, substrate specificity, and potential as a biomarker. This paves the way for novel therapeutic strategies aimed at diseases associated with DHRS7 dysfunction. As such, ongoing research into DHRS7 not only enhances our understanding of metabolic regulation but also opens new avenues for targeted therapies in related pathologies.
